138 related articles for article (PubMed ID: 37204260)
1. GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Ma J; Wang Z; Chen CC; Li M
Oncotarget; 2023 May; 14():483-484. PubMed ID: 37204260
[No Abstract] [Full Text] [Related]
2. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Xu H; Jin J; Chen Y; Wu G; Zhu H; Wang Q; Wang J; Li S; Grigore FN; Ma J; Chen CC; Lan Q; Li M
Oncogene; 2022 Jul; 41(31):3876-3885. PubMed ID: 35780181
[TBL] [Abstract][Full Text] [Related]
3. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
[TBL] [Abstract][Full Text] [Related]
4. Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Haggiagi A; Lassman AB
Neuro Oncol; 2020 Aug; 22(8):1058-1059. PubMed ID: 32479605
[No Abstract] [Full Text] [Related]
5. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based design of agents that selectively target drug-resistant glioma.
Lin K; Gueble SE; Sundaram RK; Huseman ED; Bindra RS; Herzon SB
Science; 2022 Jul; 377(6605):502-511. PubMed ID: 35901163
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
8. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract][Full Text] [Related]
9. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Brawanski KR; Sprung S; Freyschlag CF; Hoeftberger R; Ströbel T; Haybaeck J; Thomé C; Manzl C; Birkl-Toeglhofer AM
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047153
[TBL] [Abstract][Full Text] [Related]
10.
Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
[TBL] [Abstract][Full Text] [Related]
11. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
[TBL] [Abstract][Full Text] [Related]
12. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
Lozinski M; Bowden NA; Graves MC; Fay M; Day BW; Stringer BW; Tooney PA
Oncotarget; 2024 Jan; 15():1-18. PubMed ID: 38227740
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
14. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
16. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
17. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
[TBL] [Abstract][Full Text] [Related]
18. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
20. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
